Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Phil S. Baran (born August 10, 1977) is a synthetic organic chemist and Professor in the Department of Chemistry at the Scripps Research Institute. His work is focused on synthesizing complex natural products, the development of new reaction methodologies within synthetic organic electrochemistry, and the development of new reagents. He holds several patents and has authored over 300 research articles.
==== Distribution ==== Atomoxetine is well-distributed and its volume of distribution is 0.85 to 1.02 L/kg in CYP2D6 extensive metabolizers and 2.25 L/kg in CYP2D6 poor metabolizers, with its distribution being equivalent to total body water. Atomoxetine and its metabolites show only limited partitioning into red blood cells. Atomoxetine crosses the blood–brain barrier, with this appearing to be due primarily to passive diffusion rather than active transport. The drug is not a substrate of P-glycoprotein. Animal studies have found that atomoxetine and/or its metabolites can cross the placenta, but fetal exposure was substantially lower than maternal exposure. Similarly, only a small amount of atomoxetine and/or metabolites were excreted in milk in animals. Atomoxetine shows high plasma protein binding of 98.7% and is primarily bound to albumin and to a lesser extent to α1-acid glycoprotein and immunoglobulin G (IgG). Atomoxetine's limitedly active metabolite N-desmethylatomoxetine is 99.1% bound to plasma proteins, whereas its active metabolite 4-hydroxyatomoxetine shows plasma protein binding of 66.6%, which is substantially less than that of atomoxetine itself.
The lowest temperatures on record in most cities in the eastern United States were set after a mass of cold air came south from Canada. Record lows ranged from International Falls, Minnesota −45 °F (−43 °C) to Washington, D.C. and Jackson, Mississippi−5 °F (−21 °C), and were set in Milwaukee −26 °F (−32 °C), Pittsburgh −18 °F (−28 °C) and Cleveland −17 °F (−27 °C) Winston Cenac resigned as Prime Minister of Saint Lucia after 8 months in office, and was succeeded temporarily by Finance Minister Michael Pilgrim. Born: Dwyane Wade, American NBA player and team owner, 2006 MVP of the NBA Finals for the Miami Heat, inductee to the Basketball Hall of Fame, and later a minority owner of the Utah Jazz and the WNBA Chicago Sky; in Chicago Died: Varlam Shalamov, Russian writer known for Kalyma's Notes, an exposure of the horrors of Soviet labor camps, where he had been incarcerated from 1937 to 1954 Jusuf Gërvalla, 38, Albanian-born Yugoslavian Kosovo independence activist and founder of a Yugoslavian separatist group, the National Movement for the Liberation of Kosovo, was shot to death in West Germany by Yugoslavia's State Security Service. He, his brother Bardhosh Gërvalla, and another activist, Kadri Zeka, were sitting in a car in the town of Untergruppenbach when all three were killed. William Price, 86, British World War One flying ace with seven shootdowns Pierre De Cazenove De Pradines, 87, French flying ace in World War One with seven aerial victories.
Sources: en.wikipedia.org
=== Taxi === Commercial taxi services and route taxis are widely used in Moscow. During the mid-2010s, service platforms such as Yandex Taxi, Uber, and Gett displaced many private drivers and small service providers; in 2015, these platforms serviced more than 50% of all taxi orders in the city. As of 2021, Russian technology company Yandex was testing self-driving taxis in Moscow.
== Pathology == The interaction of GPX4 with the autophagic degradation pathway further modulates cell's response to oxidative stress. Impaired GPX4 function plays a role in tumorigenesis, neurodegeneration, infertility, inflammation, immune disorders, and ischemia-reperfusion injury. Additionally, the R152H mutation in GPX4 is involved in the development of Sedaghatian-type spinal metaphyseal dysplasia, a rare and fatal disease in newborn babies.
==== MeSH E05.393.525 – molecular probe techniques ==== MeSH E05.393.525.085 – biotinylation MeSH E05.393.525.100 – blotting, northern MeSH E05.393.525.150 – blotting, southern MeSH E05.393.525.225 – blotting, southwestern MeSH E05.393.525.300 – branched dna signal amplification assay MeSH E05.393.525.640 – oligonucleotide array sequence analysis MeSH E05.393.525.680 – protein array analysis MeSH E05.393.525.700 – random amplified polymorphic dna technique MeSH E05.393.525.870 – two-hybrid system techniques
Sources: en.wikipedia.org
Albumin-bound paclitaxel (brand name Abraxane, also called nab-paclitaxel) is an alternative formulation where paclitaxel is bound to albumin nanoparticles. Much of the clinical toxicity of paclitaxel is associated with the solvent Cremophor EL in which it is dissolved for delivery. Abraxis BioScience developed Abraxane, in which paclitaxel is bonded to albumin as an alternative delivery agent to the often toxic solvent delivery method. This was approved by the FDA in January 2005, for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. It has since been approved for locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas as well. Taxanes, including paclitaxel, 10-deacetylbaccatin III, baccatin III, paclitaxel C, and 7-epipaclitaxel, have been found in the leaves and shells of hazel. The finding of these compounds in shells, which are considered discarded material and are mass-produced by many food industries, is of interest for the future availability of paclitaxel.
The report argued that the UK's top-down strategy is driving vast increases in mineral demands with devastating impacts for mining-affected communities, and called for policies geared towards minimising the UK's overall mineral demands and tackling the impunity of British-listed mining corporations. Similarly, the Centre for International Governance Innovation (CIGI) has warned that the infrastructure of AI exposes a host of hidden environmental security issues, requiring international cooperation that accounts for sustainability and labour standards.
=== Occupational therapy === Occupational therapy—often abbreviated OT—is the "use of productive or creative activity in the treatment or rehabilitation of physically, cognitively, or emotionally disabled people." Most commonly, occupational therapists work with people with disabilities to enable them to maximize their skills and abilities. Occupational therapy practitioners are skilled professionals whose education includes the study of human growth and development with specific emphasis on the physical, emotional, psychological, sociocultural, cognitive and environmental components of illness and injury. They commonly work alongside clinical psychologists in settings such as inpatient and outpatient mental health, pain management clinics, eating disorder clinics, and child development services. OT's use support groups, individual counseling sessions, and activity-based approaches to address psychiatric symptoms and maximize functioning in life activities.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.